These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9731928)

  • 21. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997.
    Rahimtoola H; Egberts AC; Buurma H; Tijssen CC; Leufkens HG
    Cephalalgia; 2001 Jun; 21(5):596-603. PubMed ID: 11472386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical profile of sumatriptan: safety and tolerability.
    Lloyd K
    Eur Neurol; 1994; 34 Suppl 2():40-3. PubMed ID: 7835382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on almotriptan in migraine.
    Keam SJ; Goa KL; Figgitt DP
    CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Almotriptan: a review of its use in migraine.
    Keam SJ; Goa KL; Figgitt DP
    Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarketing surveillance of adverse drug reactions: patient self-monitoring.
    Fisher S; Bryant SG
    J Am Board Fam Pract; 1992; 5(1):17-25. PubMed ID: 1561919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.
    Lampl C; Voelker M; Diener HC
    J Neurol; 2007 Jun; 254(6):705-12. PubMed ID: 17406776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands].
    van Riemsdijk MM; Herings RM; Rawlins MD; Stricker BH
    Ned Tijdschr Geneeskd; 1995 Nov; 139(45):2306-8. PubMed ID: 7501063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exercise testing in patients with chest pain to sumatriptan.
    Ottervanger JP; Hoorntje JC; Valkenburg HA; Grobbee DE; Stricker BH
    Neth J Med; 1998 Dec; 53(6):245-8. PubMed ID: 9883001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term experience with sumatriptan in the treatment of migraine.
    Tansey MJ; Pilgrim AJ; Martin PM
    Eur Neurol; 1993; 33(4):310-5. PubMed ID: 8394239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients.
    Visser WH; Jaspers NM; de Vriend RH; Ferrari MD
    Cephalalgia; 1996 Dec; 16(8):554-9. PubMed ID: 8980858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
    Pascual J
    Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
    Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.
    Tulner LR; Kuper IM; Frankfort SV; van Campen JP; Koks CH; Brandjes DP; Beijnen JH
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):93-104. PubMed ID: 19447362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
    Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    J Psychopharmacol; 2007 Jun; 21(4):392-9. PubMed ID: 17656426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.
    Dahlöf CG; Falk L; Risenfors M; Lewis CP
    Cephalalgia; 1998 Oct; 18(8):546-51. PubMed ID: 9827246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability of the triptans: clinical implications.
    Nappi G; Sandrini G; Sances G
    Drug Saf; 2003; 26(2):93-107. PubMed ID: 12534326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.